NI201800062A - Enlazadores de ctla4 - Google Patents
Enlazadores de ctla4Info
- Publication number
- NI201800062A NI201800062A NI201800062A NI201800062A NI201800062A NI 201800062 A NI201800062 A NI 201800062A NI 201800062 A NI201800062 A NI 201800062A NI 201800062 A NI201800062 A NI 201800062A NI 201800062 A NI201800062 A NI 201800062A
- Authority
- NI
- Nicaragua
- Prior art keywords
- ctla4
- molecules
- links
- treating
- isvd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
La presente invención proporciona moléculas, tales como ISVD y Nanocuerpos, que se unen a CTLA4 o albúmina sérica humana. Estas moléculas se han diseñado con el fin de reducir la incidencia de la unión por anticuerpos preexistentes en el cuerpo de un sujeto administrado con una molécula de este tipo. Se proporcionan procedimientos para incrementar la respuesta inmunitaria, tratar el cáncer y/o tratar una enfermedad infecciosa con dichas moléculas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562257001P | 2015-11-18 | 2015-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201800062A true NI201800062A (es) | 2018-07-24 |
Family
ID=57472066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201800062A NI201800062A (es) | 2015-11-18 | 2018-05-15 | Enlazadores de ctla4 |
Country Status (30)
Country | Link |
---|---|
US (2) | US10501542B2 (es) |
EP (1) | EP3377527A1 (es) |
JP (1) | JP6768800B2 (es) |
KR (1) | KR102095140B1 (es) |
CN (1) | CN108473565B (es) |
AR (1) | AR106753A1 (es) |
AU (1) | AU2016355569B2 (es) |
BR (1) | BR112018009972B1 (es) |
CA (1) | CA3004900C (es) |
CL (1) | CL2018001326A1 (es) |
CO (1) | CO2018005161A2 (es) |
CR (1) | CR20180279A (es) |
DO (1) | DOP2018000125A (es) |
EA (1) | EA038179B1 (es) |
EC (1) | ECSP18045497A (es) |
GE (1) | GEP20207174B (es) |
HK (1) | HK1254952A1 (es) |
IL (1) | IL259173A (es) |
JO (1) | JO3739B1 (es) |
MA (1) | MA43259A (es) |
MX (1) | MX2018006246A (es) |
MY (1) | MY189590A (es) |
NI (1) | NI201800062A (es) |
PH (1) | PH12018501079A1 (es) |
SG (1) | SG11201804127SA (es) |
SV (1) | SV2018005693A (es) |
TN (1) | TN2018000169A1 (es) |
TW (1) | TWI754622B (es) |
UA (1) | UA125337C2 (es) |
WO (1) | WO2017087588A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US20180009888A9 (en) | 2011-06-23 | 2018-01-11 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
RU2746738C2 (ru) | 2014-05-16 | 2021-04-20 | Аблинкс Нв | Улучшенные вариабельные домены иммуноглобулина |
WO2017085172A2 (en) * | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
KR102317574B1 (ko) | 2015-11-18 | 2021-10-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
TWI754622B (zh) | 2015-11-18 | 2022-02-11 | 美商默沙東藥廠 | Ctla4結合劑 |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
WO2019096121A1 (en) * | 2017-11-17 | 2019-05-23 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-l1 |
WO2019179388A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-ctla-4 antibody polypeptide |
SG11202101982RA (en) | 2018-09-26 | 2021-03-30 | Ascendis Pharma As | Degradable hyaluronic acid hydrogels |
JP2022514702A (ja) | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | 二機能性抗pd-1/il-7分子 |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
CN110950957B (zh) * | 2019-12-13 | 2022-03-08 | 源道隆(苏州)医学科技有限公司 | 可结合ctla4的多肽及其应用 |
AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Ose Immunotherapeutics | Bifunctional molecules comprising an IL-7 variant |
CN115626956A (zh) * | 2020-01-16 | 2023-01-20 | 三优生物医药(上海)有限公司 | Ctla-4结合分子及其用途 |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
WO2022159575A1 (en) * | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
WO2023163968A1 (en) * | 2022-02-24 | 2023-08-31 | Merck Sharp & Dohme Llc | Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
DK1087013T3 (da) | 1992-08-21 | 2009-05-11 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
JPH08502168A (ja) | 1992-09-29 | 1996-03-12 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ニューロン細胞においてイオンチャンネル誘導活性をもつ栄養因子 |
US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
CN1203178C (zh) | 1997-10-27 | 2005-05-25 | 尤尼利弗公司 | 多价抗原结合蛋白 |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
US20020006403A1 (en) | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
ATE477275T1 (de) | 2000-12-26 | 2010-08-15 | Inst Nat Sante Rech Med | Antikörper gegen cd28 |
WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
CN101412759A (zh) | 2003-01-10 | 2009-04-22 | 埃博灵克斯股份有限公司 | 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用 |
DK1687338T3 (da) | 2003-11-07 | 2011-02-07 | Ablynx Nv | Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf |
AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
CA2588892A1 (en) | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
PL3415535T3 (pl) * | 2005-05-20 | 2021-06-14 | Ablynx N.V. | Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja |
EP1957536A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
EP1957537A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン.ヴェー. | 血清タンパク質と結合可能なペプチド |
WO2008071447A2 (en) * | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
PT2207809E (pt) | 2007-09-26 | 2013-10-09 | Amgen Inc | Proteínas de ligação a antigénio de factor de crescimento do tipo factor de crescimento epidérmico de ligação de heparina |
WO2009068630A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs |
US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
EP2315778A2 (en) | 2008-07-18 | 2011-05-04 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
US8679496B2 (en) | 2009-07-16 | 2014-03-25 | Glaxo Group Limited | Anti-serum albumin single variable domains |
WO2012175400A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Serum albumin binding proteins |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
US20180009888A9 (en) | 2011-06-23 | 2018-01-11 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
TW201321405A (zh) | 2011-08-17 | 2013-06-01 | Glaxo Group Ltd | 經修飾之蛋白質及肽 |
WO2013066765A1 (en) | 2011-11-01 | 2013-05-10 | Merck Sharp & Dohme Corp. | Mutation of tup1 in glycoengineered yeast |
CN104781277A (zh) * | 2012-09-13 | 2015-07-15 | 诺华股份有限公司 | 具有末端修饰的抗原结合分子 |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
EP3049439B1 (en) * | 2013-09-26 | 2019-12-25 | Ablynx N.V. | Bispecific nanobodies |
RU2746738C2 (ru) | 2014-05-16 | 2021-04-20 | Аблинкс Нв | Улучшенные вариабельные домены иммуноглобулина |
BR122018009619B1 (pt) | 2014-05-16 | 2024-01-02 | Ablynx N.V | Domínios variáveis de imunoglobulina aperfeiçoados |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
TWI754622B (zh) | 2015-11-18 | 2022-02-11 | 美商默沙東藥廠 | Ctla4結合劑 |
KR102317574B1 (ko) | 2015-11-18 | 2021-10-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
AU2016355568A1 (en) | 2015-11-18 | 2018-06-21 | Merck Sharp & Dohme Llc | PD1/CTLA4 Binders |
SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
-
2016
- 2016-11-17 TW TW105137708A patent/TWI754622B/zh active
- 2016-11-17 SG SG11201804127SA patent/SG11201804127SA/en unknown
- 2016-11-17 CN CN201680079309.1A patent/CN108473565B/zh active Active
- 2016-11-17 EP EP16805654.7A patent/EP3377527A1/en active Pending
- 2016-11-17 MX MX2018006246A patent/MX2018006246A/es unknown
- 2016-11-17 GE GEAP201614811A patent/GEP20207174B/en unknown
- 2016-11-17 AU AU2016355569A patent/AU2016355569B2/en active Active
- 2016-11-17 CR CR20180279A patent/CR20180279A/es unknown
- 2016-11-17 JO JOP/2016/0243A patent/JO3739B1/ar active
- 2016-11-17 JP JP2018525615A patent/JP6768800B2/ja active Active
- 2016-11-17 KR KR1020187016799A patent/KR102095140B1/ko active IP Right Grant
- 2016-11-17 EA EA201891166A patent/EA038179B1/ru unknown
- 2016-11-17 BR BR112018009972-4A patent/BR112018009972B1/pt active IP Right Grant
- 2016-11-17 US US15/353,886 patent/US10501542B2/en active Active
- 2016-11-17 UA UAA201806764A patent/UA125337C2/uk unknown
- 2016-11-17 TN TNP/2018/000169A patent/TN2018000169A1/en unknown
- 2016-11-17 MA MA043259A patent/MA43259A/fr unknown
- 2016-11-17 CA CA3004900A patent/CA3004900C/en active Active
- 2016-11-17 WO PCT/US2016/062393 patent/WO2017087588A1/en active Application Filing
- 2016-11-17 MY MYPI2018000772A patent/MY189590A/en unknown
- 2016-11-18 AR ARP160103542A patent/AR106753A1/es unknown
-
2018
- 2018-05-06 IL IL259173A patent/IL259173A/en unknown
- 2018-05-15 NI NI201800062A patent/NI201800062A/es unknown
- 2018-05-15 SV SV2018005693A patent/SV2018005693A/es unknown
- 2018-05-16 CO CONC2018/0005161A patent/CO2018005161A2/es unknown
- 2018-05-17 CL CL2018001326A patent/CL2018001326A1/es unknown
- 2018-05-18 DO DO2018000125A patent/DOP2018000125A/es unknown
- 2018-05-18 PH PH12018501079A patent/PH12018501079A1/en unknown
- 2018-06-14 EC ECIEPI201845497A patent/ECSP18045497A/es unknown
- 2018-11-02 HK HK18114056.2A patent/HK1254952A1/zh unknown
-
2019
- 2019-11-27 US US16/697,575 patent/US11649290B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201800062A (es) | Enlazadores de ctla4 | |
NI201800061A (es) | Enlazadores de pd1 y/o lag3 | |
CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
CU24427B1 (es) | Moléculas de anticuerpo que se unen a tim-3 | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
CO2018004094A2 (es) | Polipéptidos de unión a cd3 | |
UY36859A (es) | Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas | |
BR112017025191A2 (pt) | anticorpos contra ox40 e uso dos mesmos | |
CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
UY35399A (es) | Conjugados de fármacos con anticuerpos | |
BR112017002646A2 (pt) | proteínas de fusão da imunoglobulina sirp-alfa | |
ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
DK3144676T3 (da) | Kit omfattende antistof der specifikt binder til komplementfaktor b protein og antistof der specifikt binder til kulhydratantigen 19-9 protein til diagnosticering af cancer i bugspytkirtlen | |
BR112017022635A2 (pt) | anticorpo de igf-1r e seu uso para diagnóstico de câncer | |
AR119964A2 (es) | Anticuerpos anti-cd123 y conjugados y derivados de estos |